Management of severe chronic spontaneous urticaria with omalizumab

被引：0
|
作者：
Zubiaga Fernandez, Laura [1 ]
de Guzman Cejudo, Julia Rodriguez [2 ]
Bartra, Joan [3 ]
Ferrer, Marta [4 ]
Torres Jaen, Maria [5 ]
Testera Montes, Almudena [6 ]
Rondon Segovia, Carmen [7 ]
Perez Sanchez, Natalia [6 ]
Eguiluz, Ibon [8 ,9 ]
机构：
[1] Hosp Reg Univ Malaga, Malaga, Spain
[2] Hosp Reg Univ Mala, Valencia, Spain
[3] Hosp Clin Barcelona, Barcelona, Spain
[4] Clin Univ, Navarra, Spain
[5] Hosp Reg Univ Malag, Malaga, Spain
[6] Laboratorios Leti, Barcelona, Spain
[7] Reg Univ Hosp Malaga, Malaga, Spain
[8] Univ Hosp, Malaga, Spain
[9] IBIMA, Madrid, Spain
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2024年 / 153卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
210
引用
下载
收藏
页码：AB69 / AB69
页数：1
相关论文
共 50 条
  • [21] Successful treatment of severe chronic urticaria with omalizumab
    Fassihi, H.
    White, J. M.
    Benton, E.
    Morgan, G.
    Greaves, M. W.
    Grattan, C. E. H.
    BRITISH JOURNAL OF DERMATOLOGY, 2010, 163 : 52 - 53
  • [22] Omalizumab tapering and discontinuation in severe chronic urticaria
    Proenca, M.
    Vieira, J.
    Marcelino, J.
    Guimaraes, J.
    Tomaz, E.
    ALLERGY, 2023, 78 : 86 - 87
  • [23] Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series
    Netchiporouk, Elena
    Nguyen, Christopher H.
    Thuraisingham, Thusanth
    Jafarian, Fatemeh
    Maurer, Marcus
    Ben-Shoshan, Moshe
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2015, 26 (06) : 585 - 588
  • [24] Omalizumab for severe chronic spontaneous urticaria (CSU)-real life experience of 251 patients
    Vadasz, Z.
    Asher, I
    Tal, Y.
    Rotem, M.
    Shichter-Confino, V
    Greif, Y.
    Kessel, A.
    Agmon-Levin, N.
    Benor, S.
    Lachover-Roth, I
    Zeldin, Y.
    Stein, M.
    Toker, O.
    Mahlab-Guri, K.
    Bezalel-Rosenberg, S.
    Hassoun, J.
    Toubi, E.
    Sthoeger, Z.
    ALLERGY, 2017, 72 : 716 - 716
  • [25] Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients
    Vadasz, Zahava
    Tal, Yuval
    Rotem, Menachem
    Shichter-Confino, Vered
    Mahlab-Guri, Keren
    Graif, Yael
    Kessel, Aharon
    Agmon-Levin, Nancy
    Maoz-Segal, Ramit
    Kivity, Shmuel
    Benor, Shira
    Lachover-Roth, Idit
    Zeldin, Yuri
    Stein, Migel
    Toker, Ori
    Hassoun, Gamal
    Bezalel-Rosenberg, Shira
    Toubi, Elias
    Asher, Ilan
    Sthoeger, Zev
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2017, 5 (06): : 1743 - 1745
  • [26] Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria
    Gimenez-Arnau, A. M.
    Toubi, E.
    Marsland, A. M.
    Maurer, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 25 - 32
  • [27] Omalizumab Therapy for Chronic Spontaneous Urticaria: The Israeli Experience
    Rottem, Menachem
    Segal, Ramit
    Kivity, Shmuel
    Shamshines, Laliv
    Graif, Yael
    Shalit, Meir
    Kessel, Aharon
    Panasoff, Josef
    Cohen, Shai
    Toubi, Elias
    Agmon-Levin, Nancy
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2014, 16 (08): : 487 - 490
  • [28] Omalizumab in chronic spontaneous urticaria: steroid sparing effect
    Gatta, Alessia
    Della Valle, Loredana
    Farinelli, Anila
    Cavallucci, Enrico
    Paganelli, Roberto
    Di Gioacchino, Mario
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 : 6 - 9
  • [29] Chronic Spontaneous Urticaria and omalizumab: the need for personalized treatment
    Mansard, C.
    Boccon-Gibod, I
    Bouillet, L.
    ALLERGY, 2015, 70 : 483 - 483
  • [30] Treatment of Chronic Spontaneous Urticaria: a Focused Update in Omalizumab
    Blackwell, Whitney A.
    Khan, David A.
    CURRENT TREATMENT OPTIONS IN ALLERGY, 2019, 6 (03) : 175 - 188
12345